edicinal preparations containing material or reaction products thereof with undetermined constitution (A61K35)

A61K35/02 - From inanimate materials(136)
A61K35/06 - ineral oils(32)
A61K35/08 - ineral waters(229)
A61K35/10 - Peat; amber(149)
A61K35/14 - Blood(661)
A61K35/16 - Plasma; serum(392)
A61K35/18 - Erythrocytes(81)
A61K35/20 - ilk; colostrum(118)
A61K35/22 - Urine; urinary system(16)
A61K35/23 - Kidney(8)
A61K35/26 - Lymph; lymph-glands; thymus(139)
A61K35/28 - arrow; spleen(240)
A61K35/30 - Nerves; brain(140)
A61K35/34 - uscles; heart(60)
A61K35/37 - Digestive system(11)
A61K35/38 - Stomach; intestine(46)
A61K35/39 - Pancreas(70)
A61K35/407 - (77)
A61K35/413 - (38)
A61K35/42 - Lungs(21)
A61K35/48 - Reproductive organs; embryos(186)
A61K35/50 - Placenta; amniotic fluid(195)
A61K35/52 - Sperm(16)
A61K35/54 - Ovary; eggs; embryos(114)
A61K35/62 - Leeches(78)
A61K35/64 - Insects, e.g. royal jelly(443)
A61K35/68 - Protozoa(12)
A61K35/70 - (65)
A61K35/72 - (41)
A61K35/74 - Bacteria(949)
A61K35/76 - Viruses(95)
A61K35/78 - (2848)
A61K35/80 - (89)
A61K35/82 - (8)
A61K35/84 - (15)
ethod for increase of organism resistance to combined toxic action of nanoparticles of copper, zinc and lead oxides // 2642674
FIELD: medicine.SUBSTANCE: method for reduction of the adverse effects of combined effects of copper (CuO), zinc (ZnO) and lead (PbO) oxides nanoparticles on organism in risk groups covering individuals exposed to such effects under production conditions. Method includes prescription of a complex of biologically active drugs: glutaminic acid, glycine, N-acetylcysteine, pectin enterosorbent, fish oil preparation rich in unesterified omega-3 fatty acids, Vitamins A, C, D3, E, selenium, iron and iodized preparations. This complex is taken by repeated courses 1-2 times a year for 4-6 weeks daily at doses providing daily intake of 300 mg of glycine, 600 mg of cysteine, 4 g of glutaminic acid, 25 ml of fish oil with 12-15% content of polyunsaturated omega-3 fatty acids, 4-5 grams of pectin, as well as selenium, iron, iodine and these vitamins in doses that provide the normal physiological needs of the organism.EFFECT: reduction of all three metals in the blood, improved elimination function of the liver and kidneys, reduced integral signs of chronic intoxication, including signs of neurotoxicity, and genotoxic combined action of copper, zinc and lead oxides nanoparticles on the body.6 tbl
Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cells factors, c3a/s4a complement proteins, immunoglobulins and chemotactic factors // 2642650
FIELD: pharmacology.SUBSTANCE: combination of cytokines, growth factors, chemotactic factors, stem cell factors, protein complement, immunoglobulins and antibacterial/antiviral factors, taken in a specific ratio and with a specific components composition for treatment of diseases, requiring reconstruction and regeneration of tissues. A pharmaceutical composition for treatment of diseases requiring restoration and regeneration of tissues.EFFECT: combination described above and the pharmaceutical composition can effectively regenerate and restore tissues.9 cl, 2 dwg, 11 tbl, 9 ex
ethod of treating inflammatory periodontal and oral mucosal diseases // 2642648
FIELD: medicine.SUBSTANCE: method of treating inflammatory periodontal and oral mucosal diseases include the elimination of acute and inflammatory processes in the acute stage, elimination of supragingival and subgingival dental deposits, surgical and orthopedic intervention if there is evidence; oral irrigation with ozonated mineral water, optionally hydromassage, irrigation, instillation and irrigation on disease sites of periodontal tissue and oral mucosa is held with 3.5-2.5% solution of bentonite in warmed up to 38-42° C ozonized mineral water for 15-30 minutes daily for 10-14 days and it is taken inside twice a day in small sips to 100-150 ml for 14-21 days. Mineral water is used as mineral water, having the following composition: total mineralization - 1.9-2.5 g/dm3, hydrogen carbonate ions - 740-950 mg/dm3, sulfate ions - 90-140 mg/dm3, chloride ions - 500-600 mg/dm3, calcium ions - no more than 15 mg/dm3; magnesium ions - no more than 10 mg/dm3; ions of sodium and potassium - 600-800 mg/dm3, strontium - no more than 25.00 mg/dm3, chromium - not more than 0.50 mg/dm3, zinc - no more than 5.00 mg/dm3, lead - no more than 0.10 mg/dm3, mercury - not more than 0.02 mg/dm3, selenium - not more than 0.05 mg/dm3, vanadium - no more than 0.40 mg/dm3, copper - not more than 1.00 mg/dm3, cadmium - not more than 0.01 mg/dm3, nitrates - not more than 50.00 mg/dm3, nitrites - not more than 2.00 mg/dm3, fluorine - not more than 10.00 mg/dm3, arsenic - no more than 1.50 mg/dm3, phenols - not more than 0.10 mg/dm3, uranium - not more than 1.80 mg/dm3, radium - no more than 5.2×10-7 mg/dm3, organic substances in terms of carbon - 5.00-30.00 mg/dm3. In particular, mineral water can be used from the source of the resort of Saki, the Republic of Crimea, mineral water from the source of the resort of Loutraki, Greece, mineral water from the resort's source in Evpatoria, the Republic of Crimea. Montmorillonite clay Kudrinsky deposit, the Republic of Crimea can be used as bentonite.EFFECT: effective treatment, reducing the risk of recurrence of inflammatory periodontal diseases and conditions after invasive interventions of the oral mucosa.5 cl, 3 ex

Probiotic strains for treatment and/or prevention of diarrhea // 2642320
FIELD: biotechnology.SUBSTANCE: method for selection of a probiotic Bacillus strain, which includes assessment of the impact of the test strain on CFTR protein expression or NHE3 protein expression; Bacillus subtilis probiotic strain reducing CFTR protein expression and/or increasing NHE3 protein expression, deposited in the CNCM under accession number I-2745; cells obtained by cultivation of probiotic Bacillus strain, and a composition containing the effective number of cells for use in treatment and/or prevention of diarrhea.EFFECT: regulation of water absorption in the colon in the treatment and/or prevention of diarrhea.21 cl, 6 dwg, 2 ex
Probiotic bacterial strain for obtaining nutrient composition improving sleep nature // 2642301
FIELD: biotechnology.SUBSTANCE: invention relates to application of a probiotic bacterial strain Lactobacillus reuteri DSM 17938 and/or Bifidobacterium longum ATCC BAA-999 in the manufacture of a nutritional composition for a subject. At that, the REM (REM+NREM) % ratio decreases by at least 8% compared to the subject that did not take such a nutritional composition, where REM is active sleep duration (minutes), and NREM is slow sleep duration (minutes).EFFECT: invention provides normalization of the sleep nature and improves the quality of sleep.12 cl, 2 dwg, 6 tbl, 4 ex

ethod for obtaining concentrate of unsaturated alkyl-glycerine ethers from sea hydrobionts // 2642294
FIELD: food industry; pharmaceutical industry.SUBSTANCE: invention relates to the food and pharmaceutical industry, in particular to a process for the production of alkyl-glycerol esters (AGE) from marine fats. Method consists in that sea fats containing the AGE in their composition are subjected to hydrolysis to recover free fatty acids and release the unsaponifiable fraction, the mixture is neutralized with acid and crystallized from acetone to obtain a precipitate of saturated AGE, the remaining lipid mixture is evaporated, further, by chromatography on a column of silica gel and an eluting system of organic solvents, with increasing polarity, a total fraction of alkyl-glycerol esters is isolated, the solvent is evaporated, the mixture is dissolved in a non-polar organic solvent to a concentration of 0.5 to 2 % of alkyl glycerol esters and mixed with solutions of silver nitrate in 20–60 % aqueous ethanol with a non-polar:polar = 1:1–2.8, ratio, and the ratio of unsaturated alkyl-glycerols: AgNO3 = 1:3–7, mol/mol, stirred, centrifuged, the lower aqueous-ethanol layer separated, acidified with hydrochloric acid to precipitate the silver salt, filter the solution and evaporate the solvent to isolate the unsaturated alkyl-glycerol esters. Above described method takes into account the processes of interaction of silver salts with unsaturated organic compounds and allows using the advantages of this fact in the development of a simple technology for the concentration of unsaturated alkyl-glycerol esters.EFFECT: method is effective and economical for the production of unsaturated alkyl-glycerol esters from marine fats, providing not only high quality of the target product, but also the integrated use of valuable marine raw materials.4 cl, 2 dwg, 1 tbl

Cells derived from cardial tissue // 2642282
FIELD: biotechnology.SUBSTANCE: invention relates to a method for improving the contractility of the heart, increasing the capillary density, or reducing myocardial hypertrophy in a patient with a damaged myocardium, which can be used in medicine. This method includes an administration of a purified cell pool, derived from cardial tissue of a human, where these cells do not express telomerase, heavy chain of myosin, CD31, CD45 and CD16 and express GATA4, Nkx2.5, CD105, CD90, CD59 and CD54.EFFECT: invention allows you to effectively improve the contractility of the heart, increase capillary density or reduce myocardial hypertrophy in patients after acute myocardial infarction.16 cl, 39 dwg, 30 tbl, 20 ex
Application of cell line of 369 admel human skin melanoma // 2642265
FIELD: biotechnology.SUBSTANCE: specialized collection of vertebrata cell cultures of the Russian cell culture collection under the RCCC (P) registration number 727D. The cell line has stable cultural and morphological characteristics, is featured by the expression of differentiation tumor-associated antigens - MelanA, MITF, gp100, S100, tyrosinase, TRP-1; tumor-associated testis-specific antigens - NY-ESO-1 and MAGE, BAGE, GAGE, LAGE families.EFFECT: invention allows you to test the activity of various pharmaceutical products, create diagnostic sets and test systems to develop new pharmaceuticals and new therapeutic approaches, in particular, allows you to create a model system to determine the optimum doses of photosensitizer for photodynamic therapy, as well as to prepare antitumor vaccine based on activated dendritic cells.2 ex
ethod for endometritis treatment in cows // 2642251
FIELD: veterinary medicine.SUBSTANCE: ozonized autoblood as an immunomodulating and etiotropic agent is infused intramuscularly for four times in increasing-decreasing doses of 50, 75, 100, 75 ml at an interval of 48 hours, after obtaining from a vein, the blood is prepared by mixing in a syringe with 15 mg of sodium citrate and 10 mg of ozone in a ratio of 1:1 for 25 seconds, and Endometramag K is injected intramuscularly in an amount of 100.0 ml at an interval of 48 hours until recovery.EFFECT: increased effectiveness of therapeutic measures in case of endometritis and reduced period of the disease.2 tbl
Application of probiotic strain of enterococcus faecium l-3 microorganism for neurodegenerative diseases treatment // 2642246
FIELD: medicine.SUBSTANCE: probiotic strain of Enterococcus faecium L-3 is used. Therapy is carried out by short courses (up to a month) with interruptions under the control of the intestinal microbiota composition and the populations of circulating T cells. In case of exacerbations, traditional therapy with copaxone can be used (the use of a probiotic should be stopped for this period).EFFECT: method allows to increase the effectiveness of treatment by stimulating the production of anti-inflammatory cytokine.5 dwg
ethod for obtaining of dry bee royal jelly // 2641720
FIELD: food industry.SUBSTANCE: dewatering is carried out in a vacuum drying apparatus. At that, drying is performed in two stages: at the first stage, the royal jelly is concentrated at a residual pressure of 2-3 kPa and a chamber temperature of 70±3°C for 5 hours before the concentration of solids is 58-60%. At the second stage, drying is carried out to a solids concentration of 90-95% at the same residual pressure and chamber temperature of 35±3°C.EFFECT: increased efficiency of royal jelly dewatering, preservation of the thermolabile components of royal jelly.1 cl
Probiotic strain lactobacillus gasseri and its composition with lactoferrin for prevention of diarrhea, nerrocessing enterherolite and sepisis caused by escherichia coli strains in prematurely born children // 2641258
FIELD: biotechnology.SUBSTANCE: Lactobacillus gasseri strain of BK-2918D VKM having antagonistic activity against Escherichia coli strains and a composition containing the strain of Lactobacillus gasseri ECM B-2918D and lactoferrin have been claimed. Probiotic strain lactobacillus gasseri and its composition with lactoferrin for prevention of diarrhea, nerrocessing enterherolite and sepsis caused by escherichia coli strains in prematurely born children.EFFECT: expansion of the assortment of probiotic drugs and nutrient mixtures that provide the formation of normal microflora of the gastrointestinal tract in prematurely born children.2 cl, 3 dwg, 3 tbl, 7 ex

ethod of betulin nanocapsules production // 2641188
FIELD: nanotechnology.SUBSTANCE: method for preparing betulin nanocapsules in a shell of xanthan gum is described. In the process, the betulin powder is added to a suspension of xanthan gum in isopropanol in the presence of 0.01 g E472c as a surfactant with stirring at 1300 rpm. Then butyl chloride is added. The resulting suspension is filtered and dried at the room temperature. The core shell ratio is 1:1 or 1:3.EFFECT: simplification and acceleration of the nanocapsules production process and increase in yield by weight.1 dwg, 3 ex
eans for topical application in complex therapy of oral cavity diseases // 2641056
FIELD: pharmacology.SUBSTANCE: topical means for complex treatment of oral cavity diseases contains ground succinic acid introduced into the oil extract of propolis by suspension type in a weight ratio of 0.5:99.5; while the oil extract of propolis is prepared by extraction of propolis raw frozen at -10°C and ground to a powdered state with a fraction size of 0.05-0.1 mm with sunflower oil refined at room temperature for 5 days at a propolis to extractant ratio of 1:9.EFFECT: means has a strong antioxidant effect, contains no alcohol and irritants, so can be used for application to mucous membranes of the oral cavity in treatment of individuals sensitive to alcohol, or children.2 tbl

ethod for obtaining of preparation based on hymatomelanic acids of low-mineralised silt sulphidic muds // 2641046
FIELD: pharmacology.SUBSTANCE: method for obtaining of a preparation based on hyamomelanic acids from low-mineralised silt sulphidic muds, including sequential three-fold treatment of low-mineralised silt muds with a perchloric acid solution, followed by precipitate washing with water, then the precipitate is treated twice with a sodium hydroxide solution, the alkaline extracts are settled, and decanted with water, filtered, the filtrate is acidified with sulfuric acid to a pH of 1-2, kept at a temperature of 20-25°C for 24 hours, the precipitate is separated and washed with water until a negative reaction to SO42- ions, the hyamomelanic acids are extracted with ethanol until completely removed, the extract is filtered through a paper filter, ethanol is distilled off under vacuum at a temperature of 30-35°C to 1/10 of the original volume, obtained after ethanol distillation, the solution is dried with forced ventilation under certain conditions.EFFECT: shortened timeframe for final product obtaining and increased yield.1 dwg, 4 tbl, 1 ex
Lyophilised preparation of botulinum toxin // 2640922
FIELD: pharmacology.SUBSTANCE: pharmaceutical lyophilized preparation, including: botulinum toxin, polysorbate, and methionine, and one or more components selected from the group consisting of sugar, sugar alcohol and ionic compound taken at a specific ratio. The ionic compound selected from sodium chloride, sodium phosphate, ammonium phosphate, magnesium sulfate, sodium acetate, sodium succinate, sodium propionate and potassium phosphate, where the drug does not contain albumin and where the botulinum toxin stability is supported for at least 30 days at 40°C and 70% relative humidity (versions).EFFECT: compositions allow to maintain stability and activity of the preparation under high temperature conditions.11 cl, 6 tbl, 2 ex

ethod of betulin nanocapsules production // 2640499
FIELD: nanotechnology.SUBSTANCE: method for producing betulin nanocapsules is characterized in that an apple or citrus pectin is used as the nanocapsule shell, and betulin is used as the nucleus. According to the method betulin powder is added to a suspension of high- or low-etherified pectin in methanol in the presence of 0.01 g of E472c drug as a surfactant at a stirring speed of 1000 rpm, then hexane is poured in. The resulting suspension pf nanocapsules is filtered and dried at room temperature. The core: shell ratio is 1:1 or 1:3.EFFECT: according to the invention the method provides simplification and acceleration of the nanocapsules production process and increase in the yield by weight.2 dwg, 6 ex

ethod of production of nanocapsules of dorogov antiseptic excitor (dse) fraction 2 // 2640489
FIELD: nanotechnology.SUBSTANCE: method for production of Dorogov antiseptic excitor (DAE) nanocapsules fraction 2 in a shell of gellan gum is described. In the method DAE fraction 2 is added to a suspension of gellan gum in ethanol in the presence of 0.01 g of E472c drug as a surfactant at a stirring speed of 1300 rpm. Then hexane is added, the resulting precipitate is filtered and dried at room temperature. The core: shell ratio is 1:1, or 1:3, or 3:1.EFFECT: simplification and acceleration of the nanocapsules production process and increase in yield by weight.3 dwg, 4 ex

ethod and device of defrosting biomaterial // 2640427
FIELD: measuring equipment.SUBSTANCE: system includes a heating device, configured to transfer energy to a vessel, and a base, movably connected with the heating device. The system also includes a processor, configured to receive input data, associated with the target temperature, and to transfer a signal to control the movement of the heating device relative to the base for a period of time. The time period is determined on the grounds of the target temperature and fill volume, encoded in a special tag, located on the vessel. Besides the system comprises of a device, maintaining the target temperature for the whole period of using the biomaterial.EFFECT: reduction of amount of intermediate operations.24 cl, 8 dwg

Stable crystalline form of typiracyl hydrochloride and method for its crystallization // 2640417
FIELD: pharmacology.SUBSTANCE: invention relates to a new crystalline form of hydrochloride of 5-chloro-6-(2-iminopyrrolidin-1-yl)methyl-2,4(1H,3H)pyrimidinedione of the formula (I) indicated below. The crystalline form of the compound of the formula (1) shows characteristic peaks of powder X-ray diffraction at 11.6°, 17.2°, 17.8°, 23.3°, 27.1° and 29.3° angles, as the diffraction angle (2θ±0.1°) in anhydrous form and an endothermic peak determined by thermogravimetry and differential thermal analysis at a temperature of about 262 °C. The crystal shows, following crystal data in the analysis of single crystals: crystal system: monoclinic system, spatial group: P2l/n (No. 14), the crystal lattice constant: a=11.6006 (9) , b=10.3106 (11) , c=10.3036 (10) , α=90°, β=101.951 (7)°, γ=90° and unit lattice cell volume: 1205.7 (2) .EFFECT: compound has the properties of a thymidine phosphorylase inhibitor and can be used as an antitumor agent.13 cl, 3 dwg, 3 tbl, 7 ex
Probiotic bacillus megaterium strain - producer of antibacterial substances, immunomodulators and proteolytic enzymes // 2639569
FIELD: biotechnology.SUBSTANCE: Bacillus megatherium 874 strain having an immunomodulating ability is deposited in the Russian National Collection of Industrial Microorganisms under accession number VKPM V-12251 and can be used to reduce allergies and added to food.EFFECT: invention allows to expand the arsenal of probiotic strains ensuring the immune resistance of the organism and correction of dysbacteriosis of various etiologies.9 tbl, 3 ex

Lactopsillus rhamnosus bacteria suitable for eating // 2639547
FIELD: biotechnology.SUBSTANCE: Lactobacillus rhamnosus strain, intended for removal and/or neutralisation of toxic products, is deposited in CNCM under registration number I-4719. A method for obtaining of a cell fraction comprising cells culturing and Lactobacillus rhamnosus strain CNCM I-4719 isolation from the culture medium is proposed. A fraction of Lactobacillus rhamnosus cells and a composition containing a Lactobacillus rhamnosus strain CNCM I-4719, suitable for use by direct introduction into a food product, are proposed.EFFECT: increased effectiveness of animals and humans detoxification.6 cl, 4 dwg, 1 tbl, 4 ex
eans for treatment and prevention of bird gastrointestinal tract diseases // 2639544
FIELD: veterinary medicine.SUBSTANCE: Prolimizer-BioR feed additive is used as an agent for treatment and prevention of bird gastrointestinal tract diseases.EFFECT: number of birds is maintained and the live weight is increased.11 dwg, 3 tbl
ethod for intestinal flora stimulation // 2639490
FIELD: medicine.SUBSTANCE: at that, this composition is adapted for enteral administration to infants. The composition comprises at least one microorganism and at least non-digestible galactooligosaccharides, wherein the said microorganism is at least one species of Bifidobacteria selected from the group consisting of Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium bifidum, Bifidobacterium catenulatum, Bifidobacterium adolescentis and Bifidobacterium longum.EFFECT: invention allows to stimulate healthy development of intestinal flora in these infants.9 cl, 2 tbl, 6 ex
ethod for treatment of heavy liver lesion with posttraumatic coagulopathy // 2639422
FIELD: medicine.SUBSTANCE: right gastro-omental vein is excised and catheterized, through which fresh frozen plasma and platelet concentrate in a ratio of 1:1 or fresh platelet-rich plasma is transfused into the portal vein system with additional administration of 1 g tranexamic acid for 10 minutes and further administration every 8 hours for 1 g till hyperfibrinolysis reduction. Treatment is carried out under the control of thromboelastography, aggregation, APTT, PT, MHO and fibrinogen level.EFFECT: method allows to achieve maximum hemostatic effect in the wound, to correct the key pathogenetic links of post-traumatic coagulopathy and to reduce the risk of early and distant complications.1 cl
ethod for spleen lymphoid tissue reconstruction in laboratory animals // 2639404
FIELD: medicine.SUBSTANCE: laboratory animals (mice) receive intravenous allogeneic transplantation of multipotent stromal cells (MMSC) and hemopoietic stem cells (HSC) obtained from the laboratory animal placenta chorion 20 minutes after irradiation. At that, MMSC are administered at a dose of 6.2 million cells/kg, and HSC - at a dose of 330 thousand cells/kg.EFFECT: increased activation of spleen lymphoid tissue regeneration compared to other doses of stem cells introduction.2 tbl
ethod of treatment of ifn-alpha-connected states // 2639135
FIELD: medicine.SUBSTANCE: immunogenic product comprising IFNα coupled to a molecule of keyhole limpet hemocyanin (KLH), is used in therapeutically effective amount that is administered to a specified subject in one introduction which is more than 30 micrograms, and the ratio of IFNα to KLH by weight is from 0.06 to 0.6. The group of inventions also refers to a unit dosage drug form containing more than 30 μg of immunogenic product, as well as a kit for treating IFN-associatedα state of the subject in need thereof.EFFECT: neutralisation of IFNα in vivo, when more than 30 μg of the immunogenic product is used, increase of the production of IFN-binding antibodies in patients in response to the above immunogenic product.15 cl, 11 ex, 8 tbl, 5 dwg
ethod for local treatment of trophic ulcers of venous etiology // 2639123
FIELD: medicine.SUBSTANCE: method includes administration of platelet-enriched auto plasm and regional administration of lymphostimulating drugs at optimal doses with an effective course of treatment, with the autoplasm being administered sub bulcerously.EFFECT: application of the invention allows to achieve the restoration of microcirculation in the lower limbs area, more rapid disappearance of perifocal swelling, faster onset of necrolysis, emergence of granulation tissue in ulcers, accelerated reparation and epithelialization of a trophic ulcer.6 cl, 1 dwg
ethod for anal fissure treatment // 2639039
FIELD: medicine.SUBSTANCE: for treatment of a chronic anal fissure, it is excised along with the surrounding scar tissue and the guard tubercle by two half-moon incisions within healthy tissues. 0.1-0.2 ml doses of autoplasma, enriched with platelet growth factors, is injected into the wound walls and bottom with a grid of 3-4 mm. Wound edges are separated by a rectal mirror. A film of enriched autoplasm is applied to the wound bottom. Enriched autoplasm in a volume of 1 ml is injected under the wound, to a depth of 5-7 mm. Botulinum toxin A at a dose of 15-20 units is injected into the inner sphincter at three points to a depth of 5-7 mm. In case of back fissure, botulinum toxin is administered at 5, 7 and 12 hours, in case of front fissure - at 11, 1 and 6 hours. On the 4th day, the introduction of autoplasm is repeated.EFFECT: reduces postoperative pain syndrome, increases the effectiveness of anal fissure treatment, reducing the risk of postoperative complications.2 ex

ethod for obtaining of two-component preparation for treatment of joints damage by low-invasive introduction into joint bag and preparation obtained by this method // 2638796
FIELD: medicine.SUBSTANCE: method for obtaining of a two-component preparation for treatment of joint damage by low-invasive insertion of the said preparation into the joint bag, in the form of two components, the main and initiating, consisting in the fact that, in order to obtain the main component of the preparation, the blood plasma is transferred with a syringe and a transient filter with a pore size sufficient to ensure sterility, to one of the departments of the cryopack and kept until complete freezing, then the frozen blood plasma is partly defrosted, the first thawed plasma fraction is transferred to the empty compartment of the cryopack and removed from the cryopack by a syringe connected to the pack port, and the cryoprecipitate of the blood plasma remaining in the cryopack is thawed, then the cells which are chondrocyte precursors, are resuspended in the cryoprecipitate of the blood plasma in an amount sufficient to provide a therapeutic effect, and to make the initiating component of the preparation, solution of calcium chloride and thrombin is mixed in a balanced saline solution with addition of aminocaproic acid in an amount not exceeding the maximum recommended dose for a single administration in the joint bag, under certain conditions. A two-component preparation for treatment of joint damage.EFFECT: method allows for cells localization at the site of administration, allowing the cells to migrate from the glue to the damage site and maintain functional activity.8 cl, 5 dwg
ethod for treatment of myophascal neck muscle ache after gurov-levin // 2638784
FIELD: medicine.SUBSTANCE: trigger zone in neck muscles are identified and myofascial blocks are held by traumel-c drug. The drug is injected in quantity of 2.2 ml into identified trigger zones of neck muscles. After that, breath is delayed inspiratorily on the phase of "breathing in" for 9-10 seconds, while the doctor fixes the interested muscle from two sides, combines his/her breath patient's breathing and, when the patient breaths out calmly, carries out traction of this muscle with minimal effort. This complex method is repeated 5-6 times on the muscle concerned, after which the patient rests with calm rhythm of breathing for 4-5 minutes.EFFECT: method provides effective treatment of myofascial aches due to the complex - medicamental and manual effects on the background of inspiratory delay of breathing.2 ex

ethod for artificial tooth bud production in vitro and obtained artificial tooth bud // 2638783
FIELD: medicine.SUBSTANCE: method for production of an artificial tooth bud in vitro involves: a) obtaining of selected mesenchymal cells of the dental pulp; b) dental pulp mesenchymal cells culturing in a monolayer on a surface for adhesive cells; and c) dental pulp mesenchymal cells culturing under non-adhesive conditions in culture vessels with culture surface with ultra-low attachment of cells to form a cellular unit, which is an artificial tooth bud. An artificial tooth bud obtained by the above method, a transplant containing such artificial tooth bud and a pharmaceutical composition for treatment of tooth fracture and/or damage or tooth loss, containing the above artificial tooth bud or transplant, and at least one pharmaceutically acceptable excipient is proposed as well. In addition, a method for in vitro screening of substances which modulate the dental tissue properties comprising the steps: obtaining of a sample of the above artificial tooth bud, or cellular unit, or tissue derived from it; sample division into pieces; incubation of at least one part with the substance subject to screening, and comparison of parameters measured for the treated part with another part, which is not incubated with the substance subject to screening.EFFECT: method allows to produce an artificial tooth bud from adult cells to eliminate the need for embryonic cells or tissues, and only one cell type is required, namely the selected tooth pulp mesenchymal cells, or two cell types, namely the selected tooth pulp mesenchymal cells and keratinocytes; without application of any artificial biological or nonbiological frame or media that do not come from cells used in the production of the specified artificial tooth bud.15 cl, 1 ex, 16 dwg
ethod for treatment of olfactory dysfunction in patients with acute rhinosinusitis // 2638688
FIELD: medicine.SUBSTANCE: method includes application of local decongestants, irrigation, anti-inflammatory and mucolytic therapy. After acute manifestations of the disease subside, multichannel electrical stimulation is performed on the areas of the chewing muscles, nose wings muscles, the circular muscle of the mouth and the trapezium from both sides. Electrical stimulation is carried out by bipolar-pulse current with a trapezoidal envelope by a premise and a pause of 2 s, with a frequency of 20-120 MHz, current strength to low vibration of muscles under the electrodes. Exposure duration is 10-15 minutes. After this, a leech is placed on the lateral wall of the nose vestibule on one side for 10-12 minutes. The course of physiotherapeutic treatment is 4-5 combined weekly procedures.EFFECT: increased effectiveness of olfactory dysfunction treatment in patients with acute rhinosinusitis due to a multifactorial sequential action on all segments of the olfactory analyzer and the autonomic nervous system.1 ex
ethod for treatment of anal cancer with skin transition // 2638616
FIELD: medicine.SUBSTANCE: method includes two induction courses of polychemotherapy (PCT) according to the scheme: mitomycin C 10 mg/m2 intravenously sprayed on days 1 and 29 and 5-fluorouracil 1000 mg/m2 per day by continuous infusion on days 1-4 and 29-32. Three weeks after the second course of PCT, the primary focus and regional lymph nodes are exposed to external radiation of 2.4 Gy daily, 5 fractions per week till the cumulative dose of 44 isoGr, 17 irradiation sessions. At that, during 15 irradiation sessions, a sonodynamic therapy session is performed 2 hours before the start of irradiation, for which an "extempore" formulated mixture containing 5 mg of hydrogel napkin "Coletex SP-1" with propolis based on sodium alginate and 100 mg of gemcitabine is delivered to the perianal area skin. After application of the medicinal mixture, a radiator is fed to the lesion focus and a medium frequency ultrasound treatment session is performed at a frequency of 0.88 MHz, I = 1.0 Bm/cm2, exposure time 10 min. On days free from irradiation, no sonodynamic chemotherapy sessions are performed, while 15 procedures of sonodynamic exposure are performed for the entire course of external exposure. The total dose of gemcitabine for the external exposure course is 1500 mg. After the course of irradiation, a break in treatment for 2-3 weeks is performed. Then a course of endovaginal brachytherapy with a fraction dose of 3 Gy with irradiation frequency one day until a cumulative dose of 15 Gy is conducted. On days of irradiation, 2 hours before the irradiation session, a sonodynamic therapy session is performed. For this purpose, the above-mentioned "extempore" composed mixture is introduced into the anus region. Immediately after its delivery, , the radiator is fed to the focal point of the lesion and a medium frequency ultrasonic exposure session is conducted at a frequency of 0.88 MHz, I=1.0 Bm/cm2, exposure time is 10 min. In days free from irradiation, no sonodynamic chemotherapy sessions are performed. A total of 5 procedures are performed for the course of intracavitary irradiation. The total dose of gemcitabine for the course of combined radiation treatment is 2000 mg, total cumulative dose at the primary focus is 61 isoGr.EFFECT: improved effectiveness of radiation treatment, quality of life of patients with locally advanced anal cancer with transition to the skin, its complete regression.1 ex, 1 tbl
Stemptomyces virginiae strain - virginiamycine producer and method for virginiamycine production // 2637857
FIELD: biotechnology.SUBSTANCE: strain of the Streptomyces virginiae microorganism - producer of the virginiamycine antibiotic, deposited in VKM under registration number VKM Ac-2738D and method for virginiamycine antibiotic production. The method for virginiamycine antibiotic production provides cultivation of Streptomyces virginiae VKM Ac-2738D microorganism strain, antibiotic sorption from the culture fluid during biosynthesis to DIAION™ HP20 or DIAION™ HP21 polymeric resins followed by resin separation by filtering and antibiotic elution by acetone, methylene chloride or alcohols and eluate concentration in a vacuum to obtain dry matter.EFFECT: simplification of isolation and purification of the antibiotic obtained.2 cl, 7 ex
Antiproliferative agent // 2637647
FIELD: pharmacology.SUBSTANCE: agent with antiproliferative activity that is a protein extract of Toxocara canis obtained by extraction of the T. Canis helminths homogenate with a phosphate-buffered saline solution with pH of 7.2 at a ratio of 1:10 for 36-48 hours at a temperature of 4°C, centrifugation.EFFECT: pronounced antiproliferative activity.2 cl, 1 tbl, 2 ex
ethod for immune therapy of chronic viral hepatitis c // 2637631
FIELD: medicine.SUBSTANCE: patient receives autologous dendritic cells that are generated from peripheral blood cells using differentiation inducers loaded with antigens encoding viral proteins and induced to further maturation. Interleukin-2 is prescribed as adjuvant. As a antigen, a combination of fragments of recombinant viral Core (1-120 aq) and NS3 (1192-1457 aq) proteins is used, DC maturation is induced with azoximer bromide, dendritic cells are administered as 2 courses of subcutaneous vaccination, combining DC administration with subcutaneous intermittent injections of recombinant interleukin-2 as an adjuvant non-specific therapy for patients with chronic viral hepatitis C. Granulocyte-macrophage colony-stimulating factor and interferon-alpha are used as dendritic cells differentiation inducers.EFFECT: method enables an increase of clinical effectiveness.2 cl, 2 tbl, 3 ex
ethod for correction of psychosomatic diseases in patients with irritated bowel syndrome // 2637628
FIELD: medicine.SUBSTANCE: for correction of anxiety and depression in patients with irritable bowel syndrome 10 mg of "Cipralex" 1 time per day for three months, or 25 mg of "Atarax" 1 pill 2 times a day for two months and "Enterosan" 1 capsule 3 times a day 15-20 minutes before meals are prescribed for two months alongside with a diet.EFFECT: method allows to reduce regression times of pain and dyspeptic syndromes.2 ex
Dental pin for periodontitis treatment // 2637432
FIELD: medicine.SUBSTANCE: tool for introduction into the periodontal pockets of upper and lower jaws, made in the form of a pin, contains propolis and a collection of medicinal herbs, including sage leaves, medic herb, chamomile flowers, foal foot leaves, Saint-John's-wort herb, milfoil herb, calendula flowers, oak bark, peppermint leaves, dandelion leaves, taken in equal proportion as active ingredients, and alginic acid as the base with the following components content, g per pin: propolis - 1; a collection of medicinal herbs - 1; alginic acid - 1.EFFECT: composition provides a wide range of therapeutic effect, which allows to use the proposed pin for effective treatment of chronic generalized periodontitis.1 tbl, 2 ex
ethod for treatment of oral mucosa chronic inflammation with hyperkeratosis elements in young persons // 2637413
FIELD: medicine.SUBSTANCE: invention is intended for treatment of oral mucosa chronic inflammation with hyperkeratosis elements (lichen acuminatus of erosive-ulcerous form, flat form of leukokeratosis). Injection of platelet-enriched plasma 0.1-0.5 ml per mm2 is performed once a week, as a course of 3 procedures, and of placental drug "Laennek" 0.1-0.2 ml per mm2, 1 injection with an interval of 2 days, as a course of 5-10 injections, the injections are carried out under the morphological elements located on the oral mucosa and "Laennec" is additionally injected intravenously, dropwise, in a dose of 4 ml dissolved in 250-500 ml of physiological solution, for the course of 10 procedures with an interval of 2 days.EFFECT: application of the method provides long-term remission due to a complex effect on the main links of the disease pathogenesis, which is manifested in the reduction of inflammatory response, normalization of local immunity, microbial contamination of the oral fluid and stabilization of free-radical oxidation of the oral fluid.2 ex
Gingival plate for treatment of gyngivit and parodontitis // 2637411
FIELD: medicine.SUBSTANCE: gingival plate as active components contains propolis and a collection of medicinal herbs, including sage leaves, alfalfa grass, chamomile flowers, foal foot leaves, herba hyperici, milfoil grass, calendula flowers, oak bark, peppermint leaves, dandelion leaves, taken in equal proportion.EFFECT: reduction of the period of removal of inflammation in the treatment of gingivitis and periodontitis.1 tbl, 2 ex
ethod for photodynamic therapy // 2637279
FIELD: medicine.SUBSTANCE: microparticles are made from a copolymer of lactic and glycolic acids containing a photosensitizer. The obtained microparticles are added to the stem cells and their co-cultivation is carried out. After this, the stem cells are introduced to the subject with the tumour, and the tumour growth zone is exposed to light irradiation at a dose sufficient to completely or partially destroy the tumour.EFFECT: targeting effect with increased amount of the photosensitizer being transported, reducing the toxic effect of the latter on stem cells and eliminating systemic phototoxic damage.10 cl, 1 tbl, 8 ex, 2 dwg
ethod for vaginal atrophy treatment in women in postmenopause considering vaginal epithelium and microbiocenosis state // 2636619
FIELD: medicine.SUBSTANCE: bio material is taken using a vaginal or urethral probe by scraping the vagina. The number of genomic equivalents of microorganism and their fraction in the total bacterial mass are determined using the "Femoflor-16" reagent kit by real-time PCR. If the proportion of Lactobacillus spp. is more than 80%, normocenosis, characterized by the dominance of normoflora is diagnosed. If the proportion of Lactobacillus spp. is less than 80%, dysbiosis is diagnosed. At vaginal atrophy against a background of normocoenosis hormonal therapy is appointed. At a vaginal atrophy against a background of dysbiosis hormonal therapy and lactic culture containing preparations are appointed.EFFECT: invention provides development of individual approaches to vaginal atrophy treatment in postmenopausal women, taking into account the state of the vaginal biocenosis.5 tbl, 3 ex
ethod for reconstruction of immunological disorders in newborn calves // 2636491
FIELD: veterinary medicine.SUBSTANCE: method includes application of xymedone in combination with L-ascorbic acid and saline solution and additionally OCC "Furor" as follows: on day 1, 2 and 7 of life: IM xymedone in combination with L-ascorbic acid and saline solution at the following component ratio, wt %: xymedone - 13.22, L-ascorbic acid - 4.13, saline -the rest at a dose of 52.5 mg/kg of body weight, OCC "Furor" starting from the second day of life for 10 days inside with milk or colostrum at a dose of 0.3 ml/kg of body weight.EFFECT: increased serum bactericidal activity and serum lysozymic activity, increased number of T-and B-lymphocytes, phagocytic activity of blood neutrophils, adaptation to environmental changes and high antigen load, greater resistance to gastrointestinal diseases.7 tbl, 3 ex
Pharmaceutical composition for thermal injuries and wounds treatment in combination with bone damage // 2636227
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for treatment of wounds complicated by bone damage, which consists of 4 wt % to 12 wt % of beeswax and 88 wt % to 96 wt % of an extract obtained with sesame oil from initial ingredients including Radix Scutellariae, Coptis Chinensis, Cortex Phellodendri, Pericarpium Papaveris and Lumbricus, based on the total weight of the composition. Individual content of each of Radix Scutellariae, Coptis Chinensis, Cortex Phellodendri, Pericarpium Papaveris and Lumbricus, based on their dry weight, ranges from 1% to 6% of the total weight of sesame oil, respectively. Application of the pharmaceutical composition for manufacture of a drug for treatment of a thermal injury complicated by bone damage. A pharmaceutical composition for treatment of a thermal injury complicated by bone damage. A method for treatment of open injuries complicated by a fracture, a deep thermal injury with bone damage or bone necrosis.EFFECT: composition has increased effectiveness for treatment of wounds and thermal injuries complicated by bone damage.9 cl, 31 dwg, 8 ex
Probiotic strains for application in osteoporosis treatment or prevention // 2636027
FIELD: biotechnology.SUBSTANCE: application of the probiotic strain Lactobacillus paracasei 8700:2, DSM 13434 and the use of the strain Lactobacillus paracasei 8700:2, DSM 13434 in combination with at least one of Lactobacillus plantarum strains for osteoporosis treatment or prevention, bone tissue treatment or prevention, for Ca2+ ions absorption increase in a mammal. Application of the probiotic strain Lactobacillus paracasei 8700:2, DSM 13434 in combination with Lactobacillus plantarum HEAL 9, DSM 15312 and Lactobacillus plantarum HEAL 19, DSM 15313 for osteoporosis treatment or prevention, bone tissue treatment or prevention, for Ca2+ ions absorption increase in a mammal is proposed.EFFECT: reduced cortical bone loss in treatment of postmenopausal osteoporosis.24 cl, 6 dwg, 3 tbl, 4 ex
ethod of surgical treatment of patients with arnold-chiari malformation // 2635862
FIELD: medicine.SUBSTANCE: Y-shaped dissection of the dura mater (DM) is carried out before the release of cerebellum tonsils and subsequent plastication of the formed defect. Wherein, additional plastic is performed on artificial DM. To do this, the edges of DM and the formed flap of artificial DM are glued with the help of Tissukol Kit or BioGlue adhesive compositions, which are applied with the help of a doveplication system and an application needle.EFFECT: method helps to reduce postoperative complications, which is achieved by performing additional plastics of dura mater.1 cl
Wound closure and healing dressing // 2635533
FIELD: medicine.SUBSTANCE: dressing on a net material with beeswax is described, into which petrolatum and/or petroleum jelly is added in an amount of 5÷95 wt.%. Plastification of beeswax with a vaseline composition and use of a net material in the dressing structure to apply a plasticized wax composition, introduction of medicinal products, including hydrophilic, and surface active substances into the dressing.EFFECT: dressing resistance to oxidation, to radiation sterilization, stability of the dressing properties for prolonged storage over a wide range of temperatures, controlled wound modeling, as well as therapeutic effect, steam and gas permeability.8 cl, 1 tbl, 20 ex
ethod for prevention of acute respiratory diseases of bacterial etiology and tonsillitises in period of organized collectives formation // 2635519
FIELD: medicine.SUBSTANCE: members of the collective during the seasonal increase in the incidence of acute respiratory diseases receive aerosol oropharyngeal streptococcal bacteriophage preparation or pyobacteriophage preparation, 1.5-2 ml in the morning and evening 30-60 minutes before or after meals, for 10-14 days.EFFECT: prevention of the incidence of acute respiratory diseases of bacterial etiology and tonsillitis among members of organized collectives.3 ex, 4 tbl

Cell content removal and recovery in organs and tissues // 2635478
FIELD: medicine.SUBSTANCE: vascular tissue of a pig, cow, sheep, dog or human, deprived of cells by perfusion, containing cell-free extracellular matrix of the said tissue is proposed. This extracellular matrix includes a vascular tree. This cell-free extracellular matrix of the said tissue retains most of the fluid introduced into the said vascular tree of the cell-free extracellular matrix. A method for cell removal from the tissue by perfusion is proposed, as well as a part of an organ with cells removed by perfusion.EFFECT: possibility of effective reconstruction of organ or tissue.16 cl, 2 dwg